Quick Answer
Aclaris Therapeutics, Inc. reported Total Revenue of $7.83 million for fiscal year 2025.
Aclaris Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $7.83M -58.2% |
$18.72M -40.1% |
$31.25M +5.0% |
$29.75M +340.1% |
$6.76M +4.3% |
$6.48M +53.3% |
| Revenue (ASC 606) | $7.83M -58.2% |
$18.72M -40.1% |
$31.25M +5.0% |
$29.75M +340.1% |
$6.76M +4.3% |
$6.48M +53.3% |
| Net Income | -$64.92M +50.8% |
-$132.06M -49.3% |
-$88.48M -1.8% |
-$86.91M +4.4% |
-$90.86M -78.1% |
-$51.02M +68.4% |
| Diluted EPS | -$0.53 +69.0% |
-$1.71 -34.6% |
-$1.27 +4.5% |
-$1.33 +16.9% |
-$1.60 -33.3% |
-$1.20 +69.2% |
| Total Assets | $160.46M -27.2% |
$220.33M +11.6% |
$197.41M -22.5% |
$254.60M +1.3% |
$251.21M +254.9% |
$70.78M -28.0% |
| Cash and Equivalents | $19.96M -18.8% |
$24.57M -38.4% |
$39.88M -11.9% |
$45.28M +65.6% |
$27.35M +24.0% |
$22.06M -35.5% |
| Long-Term Debt | — | — | — | — | — | $10.65M |
| Stockholders Equity | $103.08M -33.7% |
$155.55M -1.0% |
$157.18M -20.5% |
$197.62M +0.1% |
$197.34M +424.1% |
$37.65M -46.1% |
| R&D Expense | $52.65M +56.7% |
$33.59M -65.9% |
$98.38M +26.4% |
$77.81M +77.6% |
$43.81M +49.3% |
$29.34M -54.3% |
| Operating Income | -$76.38M +46.2% |
-$141.93M -45.8% |
-$97.36M -8.4% |
-$89.85M -0.1% |
-$89.72M -76.2% |
-$50.91M +54.2% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 120.50M +11.7% |
107.85M +52.1% |
70.89M +6.3% |
66.69M +8.9% |
61.23M +35.7% |
45.11M +8.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.30M | -24.1% | +85.6% |
| Revenue (ASC 606) | September 30, 2025 | $3.30M | -24.1% | +85.6% |
| Net Income | September 30, 2025 | -$14.61M | -92.6% | +5.3% |
| Diluted EPS | September 30, 2025 | -$0.12 | -9.1% | +7.7% |
| Total Assets | September 30, 2025 | $175.53M | -3.8% | -7.2% |
| Cash and Equivalents | September 30, 2025 | $25.26M | -47.0% | -0.6% |
| Long-Term Debt | June 30, 2021 | $10.73M | +1.5% | +0.4% |
| Stockholders Equity | September 30, 2025 | $120.10M | -7.7% | -8.8% |
| R&D Expense | September 30, 2025 | $13.03M | +118.7% | +13.8% |
| Operating Income | September 30, 2025 | -$17.15M | -63.8% | +6.8% |
| Gross Profit | September 30, 2018 | $435.0K | +88.3% | -82.6% |
| Shares Outstanding | September 30, 2025 | 108.34M | +51.7% | +0.0% |
- Aclaris Therapeutics, Inc. reported Total Revenue of $7.83 million for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed a decrease of -58.2% in Total Revenue compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Revenue (ASC 606) of $7.83 million for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed a decrease of -58.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Net Income of -$64.92 million for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed an increase of +50.8% in Net Income compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Diluted EPS of $0.53 per share (loss) for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed an increase of +69.0% in Diluted EPS compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Total Assets of $160.46 million for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed a decrease of -27.2% in Total Assets compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Cash and Equivalents of $19.96 million for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed a decrease of -18.8% in Cash and Equivalents compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Long-Term Debt of $10.65 million for fiscal year 2020.
- Aclaris Therapeutics, Inc. showed a decrease of -64.4% in Long-Term Debt compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Stockholders Equity of $103.08 million for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed a decrease of -33.7% in Stockholders Equity compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported R&D Expense of $52.65 million for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed an increase of +56.7% in R&D Expense compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Operating Income of -$76.38 million for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed an increase of +46.2% in Operating Income compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Gross Profit of $3.24 million for fiscal year 2018.
- Aclaris Therapeutics, Inc. showed an increase of +580.9% in Gross Profit compared to the prior fiscal year.
- Aclaris Therapeutics, Inc. reported Shares Outstanding of 120.50 million shares for fiscal year 2025.
- Aclaris Therapeutics, Inc. showed an increase of +11.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: